We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Bitplane Imaris to Identify Novel Role for CD169+ Macrophages in Activating Invariant Natural Killer T Cells

Product News   Mar 31, 2011

 
Bitplane Imaris to Identify Novel Role for CD169+ Macrophages in Activating Invariant Natural Killer T Cells
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Pathios Therapeutics Awarded Grant To Accelerate Cancer Immunotherapy Programme

Product News

Pathios Therapeutics Limited today announced that it has been awarded £350K (approximately US$475K) in the form of a Smart Grant from Innovate UK, the UK Government’s innovation agency, to accelerate their cancer immunotherapy program targeting the innate immune checkpoint, GPR65.

READ MORE

Vivan Therapeutics Joins Repositive Cancer Model Network

Product News

Repositive has announced that Vivan Therapeutics will be the next company to join its global network of cancer model partners. With this new partnership, Repositive is expanding its personalized medicine capabilities to support more biopharma customers in their oncology drug development programs.

READ MORE

Patient-Derived Human Primary Cancer Cells

Product News

AMSBIO has expanded its range of primary human cancer cells sourced from a wide variety of tissue types that allow the study of cancer in a more in vivo like fashion.

READ MORE

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE